Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $15.08 which represents a decrease of $-0.01 or -0.07% from the prior close of $15.09. The stock opened at $15.46 and touched a low of $14.9 ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TXG stock, giving a Buy rating on January 13.Stay Ahead of the ...

Stifel Nicolaus analyst Daniel Arias has maintained their bullish stance on TXG stock, giving a Buy rating yesterday.Stay Ahead of the ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.98 which represents a decrease of $-0.46 or -2.98% from the prior close of $15.44. The stock opened at $16.11 and touched a low of ...

Genomics is innovating in spatial technologies but faces hurdles. Discover why TXG stock’s price/cashflow ratio and competition warrant a Sell rating.

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:TXG), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes ...

Shares of 10X Genomics (NASDAQ:TXG) climbed 7% as the company reported preliminary fourth-quarter sales that surpassed analyst expectations. The life sciences company, known for its work in single ...